Here are what the editors at HealthDay consider to be the most important developments in Allergy for August 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
LABA Withdrawal Increases Asthma-Related Impairment
TUESDAY, Aug. 28 (HealthDay News) -- For patients with asthma controlled with a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA), withdrawal of the LABA once asthma is controlled correlates with increased asthma-associated impairment, according to a study published online Aug. 27 in the Archives of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Gabapentin Efficacious for Refractory Chronic Cough
TUESDAY, Aug. 28 (HealthDay News) -- For patients with refractory chronic cough, treatment with gabapentin is associated with improved cough-specific quality of life and is well-tolerated, according to a study published online Aug. 28 in The Lancet.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Opportunistic Infections Associated With Antibodies to IFN
WEDNESDAY, Aug. 22 (HealthDay News) -- Neutralizing anti-interferon-γ autoantibodies are detected in most Asian adults with multiple opportunistic infections, according to a study published in the Aug. 23 issue of the New England Journal of Medicine.
Full Text (subscription or payment may be required)
Ecallantide Efficacious for Hereditary Angioedema Attacks
FRIDAY, Aug. 17 (HealthDay News) -- Patients with unpredictable and recurring attacks of acute hereditary angioedema (HAE) may be effectively treated with ecallantide, with relapse occurring in a small proportion of patients and little evidence of rebound, according to a study published in the September issue of Allergy.
Abstract
Full Text (subscription or payment may be required)
Mepolizumab Effective in Treating Eosinophilic Asthma
FRIDAY, Aug. 17 (HealthDay News) -- For patients with severe eosinophilic asthma, treatment with mepolizumab, a monoclonal antibody against interleukin 5, is effective at reducing clinically significant exacerbations, according to a study published in the Aug. 18 issue of The Lancet, a theme issue on respiratory medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
High IgE Levels Inversely Associated With Risk of Glioma
THURSDAY, Aug. 9 (HealthDay News) -- There appears to be an inverse relationship between elevated allergy biomarker levels (immunoglobulin E [IgE]) and the risk of developing glioma, which is detectable many years before tumor diagnosis, according to a study published online Aug. 1 in the Journal of the National Cancer Institute.
Abstract
Full Text
Oral Corticosteroids Deemed Ineffective for Rhinosinusitis
TUESDAY, Aug. 7 (HealthDay News) -- Systemic corticosteroids are not effective for symptom control in patients with acute rhinosinusitis, according to a study published online Aug. 7 in CMAJ, the journal of the Canadian Medical Association.
Abstract
Full Text
Clinicians Can Unintentionally Prompt Nocebo Effect
THURSDAY, Aug. 2 (HealthDay News) -- The nocebo effect, or induction of a symptom perceived as negative by sham treatment and/or the suggestion of negative expectation, may arise from suggestions by doctors and nurses, according to a study published in Deutsches Ärzteblatt International.
Full Text
